中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2013年
9期
674-678
,共5页
武博荣%郑艳丽%桑贤良%金盟%王卫真%张庆山%赵素贤%孔丽
武博榮%鄭豔麗%桑賢良%金盟%王衛真%張慶山%趙素賢%孔麗
무박영%정염려%상현량%금맹%왕위진%장경산%조소현%공려
肝硬化%肝星状细胞%机制
肝硬化%肝星狀細胞%機製
간경화%간성상세포%궤제
Liver cirrhosis%Hepatic stellate cells%Mechanism
目的 探讨胰岛素样生长因子(IGF)-1和磷脂酰肌醇3-激酶(PI3K)信号通路在自发逆转肝纤维化模型中的动态变化及扶正化瘀方对其影响的机制. 方法 实验大鼠分为对照组、自发逆转模型组(模型组)与扶正化瘀组.模型组和扶正化瘀组以四氯化碳(CCl4)腹腔注射8周以建立肝纤维化模型,8周后模型组停用CCl4观察至14周,扶正化瘀组自CCl4造模同时以扶正化瘀方灌胃至8周.观察血清ALT、AST变化,用HE和Masson染色观察肝组织炎症和纤维化程度,免疫组织化学和RT-PCR法检测肝组织α-平滑肌肌动蛋白、IGF-1、PI3K蛋白和mRNA表达.多组数据间比较采用单因素方差分析,Student-Newman-Keuls法进行组间比较,相关分析采用直线相关分析法. 结果 随CCl4造模时间延长,模型组大鼠肝组织炎症及纤维化逐渐加重,Ishak评分,羟脯氨酸含量、α-平滑肌肌动蛋白及IGF-1、PI3K蛋白和mRNA表达逐渐升高,8周时达高峰.停用CCl4后随肝组织炎症和纤维化好转,Ishak评分、羟脯氨酸含量、α-平滑肌肌动蛋白表达及IGF-1、PI3K蛋白和mRNA表达亦逐渐降低,到14周时各指标达到最低;扶正化瘀组第4、6、8周各时间点大鼠肝组织炎症和纤维化程度,Ishak评分,羟脯氨酸含量,α-平滑肌肌动蛋白,IGF-1和PI3K蛋白及mRNA表达均较模型组相同时间点明显降低.结论 IGF-1和PI3K信号通路在肝纤维化发生和逆转中发挥重要作用,扶正化瘀方可通过阻断IGF-1、PI3K信号通路及减少肝星状细胞活化等作用发挥抗肝纤维化功效.
目的 探討胰島素樣生長因子(IGF)-1和燐脂酰肌醇3-激酶(PI3K)信號通路在自髮逆轉肝纖維化模型中的動態變化及扶正化瘀方對其影響的機製. 方法 實驗大鼠分為對照組、自髮逆轉模型組(模型組)與扶正化瘀組.模型組和扶正化瘀組以四氯化碳(CCl4)腹腔註射8週以建立肝纖維化模型,8週後模型組停用CCl4觀察至14週,扶正化瘀組自CCl4造模同時以扶正化瘀方灌胃至8週.觀察血清ALT、AST變化,用HE和Masson染色觀察肝組織炎癥和纖維化程度,免疫組織化學和RT-PCR法檢測肝組織α-平滑肌肌動蛋白、IGF-1、PI3K蛋白和mRNA錶達.多組數據間比較採用單因素方差分析,Student-Newman-Keuls法進行組間比較,相關分析採用直線相關分析法. 結果 隨CCl4造模時間延長,模型組大鼠肝組織炎癥及纖維化逐漸加重,Ishak評分,羥脯氨痠含量、α-平滑肌肌動蛋白及IGF-1、PI3K蛋白和mRNA錶達逐漸升高,8週時達高峰.停用CCl4後隨肝組織炎癥和纖維化好轉,Ishak評分、羥脯氨痠含量、α-平滑肌肌動蛋白錶達及IGF-1、PI3K蛋白和mRNA錶達亦逐漸降低,到14週時各指標達到最低;扶正化瘀組第4、6、8週各時間點大鼠肝組織炎癥和纖維化程度,Ishak評分,羥脯氨痠含量,α-平滑肌肌動蛋白,IGF-1和PI3K蛋白及mRNA錶達均較模型組相同時間點明顯降低.結論 IGF-1和PI3K信號通路在肝纖維化髮生和逆轉中髮揮重要作用,扶正化瘀方可通過阻斷IGF-1、PI3K信號通路及減少肝星狀細胞活化等作用髮揮抗肝纖維化功效.
목적 탐토이도소양생장인자(IGF)-1화린지선기순3-격매(PI3K)신호통로재자발역전간섬유화모형중적동태변화급부정화어방대기영향적궤제. 방법 실험대서분위대조조、자발역전모형조(모형조)여부정화어조.모형조화부정화어조이사록화탄(CCl4)복강주사8주이건립간섬유화모형,8주후모형조정용CCl4관찰지14주,부정화어조자CCl4조모동시이부정화어방관위지8주.관찰혈청ALT、AST변화,용HE화Masson염색관찰간조직염증화섬유화정도,면역조직화학화RT-PCR법검측간조직α-평활기기동단백、IGF-1、PI3K단백화mRNA표체.다조수거간비교채용단인소방차분석,Student-Newman-Keuls법진행조간비교,상관분석채용직선상관분석법. 결과 수CCl4조모시간연장,모형조대서간조직염증급섬유화축점가중,Ishak평분,간포안산함량、α-평활기기동단백급IGF-1、PI3K단백화mRNA표체축점승고,8주시체고봉.정용CCl4후수간조직염증화섬유화호전,Ishak평분、간포안산함량、α-평활기기동단백표체급IGF-1、PI3K단백화mRNA표체역축점강저,도14주시각지표체도최저;부정화어조제4、6、8주각시간점대서간조직염증화섬유화정도,Ishak평분,간포안산함량,α-평활기기동단백,IGF-1화PI3K단백급mRNA표체균교모형조상동시간점명현강저.결론 IGF-1화PI3K신호통로재간섬유화발생화역전중발휘중요작용,부정화어방가통과조단IGF-1、PI3K신호통로급감소간성상세포활화등작용발휘항간섬유화공효.
Objective To determine the role of IGF-1/PI3K pathway and investigate the molecular mechanism of Fuzhenghuayu (FZHY) therapy in a spontaneous recovery rat model of liver fibrosis.Methods The liver fibrosis model was induced in male Wistar rats by administering 8 weeks of twice weekly CCL4 intraperitoneal injections without (untreated model) or with once daily FZHY (treated model).Normal,untreated rats served as the control group.At weeks 4,6 and 8 (fibrosis) and 10,12 and 14 (spontaneous recovery) after modeling initiation,effects on protein (α-SMA,IGF-1,PI3K) and mRNA (IGF-1,PI3K) expression levels were evaluated by immunohistochemistry and RT-PCR,respectively.Serum markers of liver function (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and liver cell damage (alkaline hydrolysis,HYP) were measured.Histology was performed to assess the degree of inflammation and fibrosis (Ishak scoring system).Results In the untreated model group,progression of liver fibrosis (weeks 4,6 and 8) was accompanied by gradual increases in inflammation,necrosis,serum ALT and AST,and hepatic expression of α-SMA protein and IGF-1 and PI3K protein and mRNA; however,during the spontaneous recovery period (weeks 10,12 and 14) the IGF-1 and PI3K protein and mRNA levels rapidly decreased and the HYP level,Ishak score,and α-SMA hepatic expression also decreased.The FZHY-treated model group showed significantly lower fibrosis-related up-regulation of IGF-1 and PI3K protein and mRNA expression,HYP level,Ishak score,and α-SMA hepatic expression at each time point (vs.untreated model group).Conclusion The IGF-1/PI3K pathway may contribute to progression of liver fibrosis.The mechanism by which FZHY prevents liver fibrosis in a rat model may involve blocking of the IGF/PI3K pathway and inhibiting HSC activation.